Preliminary safety, antitumor activity, and circulating tumor DNA (ctDNA) changes with RMC-9805, an oral, RAS(ON) G12D-selective tri-complex inhibitor in patients with KRAS G12D pancreatic ductal ...

Pancreatic cancer is one of the deadliest of all cancers. Only 12% of men diagnosed with pancreatic cancer are alive five years after diagnosis; for women it is 14%. In pancreatic cancer, symptoms ...

Copyright: © 2024 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.

Although increased understanding of the molecular background to pancreatic cancer can certainly ... monoclonal antibodies, EGFR inhibitors, COX2 inhibitors and circumvention of hENT1 in ...

Tyrosine (Tyr) phosphorylation of p27 by Abl and Src family kinases reduces p27–CDK2 inhibition and transforms p27 from inhibitor to substrate of cyclin–CDK2 complexes. p27 phosphorylation at ...

Pancreatic cancer is a highly lethal digestive malignancy with a 5-year survival rate of 10%. So far, the available therapeutic strategies are scarce and the few advancements made, as is the case of ...

These next-generation STAT6 inhibitors demonstrate excellent oral bioavailability, cell permeability, and metabolic stability, and do not target STAT6 for degradation. DeepCure expects to select a ...

The drug, Mesupron (upamostat), is a proprietary, first-in-class, orally administered protease inhibitor for the adjuvant treatment of pancreatic cancer. It has several potential mechanisms ... the ...